0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About TetraLogic Pharmaceuticals
Its shares trade under the ticker TLOG. It has been listed since 12 December 2013.
TetraLogic Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel small molecule therapeutics in oncology and infectious diseases. The company is headquartered in Malvern, Pennsylvania. The company went IPO on 2013-12-12. The firm is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The firm's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The firm has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The firm is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Dec 2013
- Employees
- 29
- Website
- infinitepaving.com ↗
Leadership
Pay as last reported
- Mr. J. Kevin BuchiPresident, Chief Executive Officer, Director, since 2013$563,532
- Dr. Mary GrayDirector, since 2014
- Mr. Patrick HutchisonChief Financial Officer, Vice President - Finance, Treasurer, since 2016
- Mr. Michael KishbauchDirector, since 2014
- Dr. Anthony MeehanChief Operating Officer
- Dr. Andrew PecoraIndependent Chairman of the Board, since 2013
- Mr. Paul SchmittIndependent Director, since 2003
- Mr. Richard ShermanSenior Vice President - Strategic Transactions, General Counsel, Secretary$954,669
- Dr. Doug ReedIndependent Director, since 2010
- Mr. Pete MeyersChief Financial Officer, Treasurer, since 2013$438,360
- Dr. C. Glenn BegleySenior Vice President - Research & Development, Chief Scientific Officer, since 2013$512,032
- Dr. Lesley RussellChief Operating Officer, Chief Medical Officer, since 2014$438,552
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- TetraLogic Pharmaceuticals Corp. focuses on oncology and infectious diseases with two clinical-stage product candidates.
- SHAPE has received U.S. orphan drug designation for CTCL treatment in early-stage cutaneous T-cell lymphoma.
- The company employs 29 full-time staff in Malvern, Pennsylvania, specializing in biopharmaceutical development.
Weaknesses
- The company has only two clinical-stage product candidates in development for oncology and infectious diseases.
- TetraLogic's focus on small molecule therapeutics limits its pipeline diversity in biotechnology.
- With 29 employees, the company has a small operational scale for a clinical-stage biopharmaceutical firm.
Opportunities
- SHAPE's exploration in alopecia areata offers a new autoimmune disease treatment opportunity.
- The U.S. orphan drug designation for CTCL may accelerate SHAPE's regulatory approval process.
- Expanding SHAPE's use to topical applications could open new markets in dermatology.
Threats
- Birinapant's development as a SMAC-mimetic therapeutic faces competition in oncology treatments.
- The biotechnology sector's high R&D costs could strain TetraLogic's limited resources.
- Regulatory hurdles for clinical-stage biopharmaceuticals may delay product launches.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.